CRIS Current Research Information System

BRIGNOLA, CORRADO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 641
EU - Europa 523
AS - Asia 52
AF - Africa 41
OC - Oceania 2
Totale 1.259
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 637
SE - Svezia 200
DE - Germania 90
IE - Irlanda 79
GB - Regno Unito 49
IT - Italia 36
BG - Bulgaria 33
CI - Costa d'Avorio 21
JO - Giordania 21
TG - Togo 18
CH - Svizzera 17
IN - India 16
IR - Iran 10
FI - Finlandia 9
FR - Francia 7
CA - Canada 4
SG - Singapore 3
AU - Australia 2
CN - Cina 2
RO - Romania 2
BE - Belgio 1
NG - Nigeria 1
ZA - Sudafrica 1
Totale 1.259
Salva come PNG Salva come JPEG
Città #
Chandler 182
Dublin 79
Princeton 72
Ashburn 67
Southend 46
Berlin 35
Sofia 31
Abidjan 21
Amman 21
Lomé 18
Bern 17
Fairfield 10
Helsinki 8
Milan 8
Washington 7
Frankfurt am Main 6
Houston 6
Olalla 6
San Diego 6
Woodbridge 6
Bologna 5
Los Angeles 5
New York 5
Nuremberg 5
Perugia 5
Turin 5
Cambridge 3
Paris 3
Zanjan 3
Andover 2
Augusta 2
Boardman 2
Bühl 2
Guangzhou 2
Hamburg 2
Leawood 2
Montreal 2
Piacenza 2
Prato 2
Prescot 2
Redmond 2
Sacramento 2
Seattle 2
Ann Arbor 1
Baia Mare 1
Boydton 1
Bremen 1
Brussels 1
Buffalo 1
Büdelsdorf 1
Cedar Knolls 1
Chicago 1
Council Bluffs 1
Henderson 1
Lagos 1
Lappeenranta 1
Naples 1
Napoli 1
Pisa 1
Pune 1
Raleigh 1
San Lazzaro di Savena 1
Sebokeng 1
Suffern 1
Toronto 1
Torre Del Greco 1
Wilmington 1
Winnipeg 1
Totale 744
Salva come PNG Salva come JPEG
Nome #
5-Aminosalicylic acid in patients with ulcerative colitis in remission: plasma levels after administration of a new rectal enema 79
5-Aminosalicylic acid suppositories in the management of ulcerative colitis 66
5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? 59
Analysis of biological variables in Crohn's disease [4] 53
[Abdominal scintigraphy with leukocytes marked with indium-111 in Crohn disease: clinical importance and prognostic usefulness] 50
5-Aminosalicylic acid for the treatment of inflammatory bowel diseases 49
Bioavailability of single and multiple doses of a new oral formulation of 5‐ASA in patients with inflammatory bowel disease and healthy volunteers 46
Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion 45
Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis 45
A Possible mechanism of action of sulfasalazine and 5-aminosalicylic acid in inflammatory bowel diseases: Interaction with oxygen free radicals 43
Changes in splanchnic hemodynamics in inflammatory bowel disease non-invasive assessment by doppler ultrasound flowmetry 42
Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients 39
Macrophage subpopulations in pouchitis 38
Respiratory burst of circulating polymorphonuclear leukocytes and plasma elastase levels in patients with inflammatory bowel disease in remission 37
Influence of steroid treatment's duration in patients with active Crohn's disease 36
Lack of effect of antineutrophil cytoplasmic antibodies associated with ulcerative colitis on superoxide anion production from neutrophils 35
Scavenger effect of sulphasalazine (SASP), 5-aminosalicylic acid (5-ASA), and olsalazine (OAZ) (I) 34
Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation 33
Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis 32
Bronchopulmonary involvement in ulcerative colitis 32
Role of rectal formulations: Enemas 31
Optimum dosage of 5-Aminosalicylic acid as rectal enemas in patients with active ulcerative colitis 31
Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis 31
Enhanced mucosal interleukin-6 and -8 in Helicobacter pylori-positive dyspeptic patients 30
Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis 30
Requirements for the use of intestinal action antibiotics in the treatment of ulcerative colitis 30
Interleukin 1 beta (IL-1 beta) release from fresh and cultured colonic mucosa in patients with ulcerative colitis (UC) 29
Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation - A double-blind placebo controlled trial 29
Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease 27
Interleukin 1 in ulcerative colitis 27
Short report: zinc sulphate supplementation corrects abnormal erythrocyte membrane long‐chain fatty acid composition in patients with Crohn's disease 26
Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis 25
Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis 20
Pentasa in maintenance treatment of ulcerative colitis 20
Systemic availability of 5-aminosalicylic acid: Comparison of delayed release and an azo-bond preparation 19
Mucosal concentrations of interleukin-1β, interleukin-6, interleukin-8, and tumor necrosis factor-α in pelvic ileal pouches 18
Factors affecting recurrence in Crohn's disease: Results of a prospective audit 2
Totale 1.318
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.259
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.259
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022386 0 0 0 0 0 0 0 0 133 52 153 48
2022/2023752 72 114 69 48 45 59 21 59 146 22 34 63
2023/2024180 13 33 17 16 18 49 3 11 4 16 0 0
Totale 1.318